SINGAPORE healthtech startup Biofourmis is collaborating with Swiss pharmaceutical giant Novartis to start a digital therapeutics programme for patients with heart failure in South-east Asia, it announced on Monday.
Through the partnership, patients on Novartis' heart failure medication will also be prescribed Biofourmis' digital therapeutics programme to monitor recovery for at least three months. The programme hopes to reach out to one million patients suffering from heart failure in the region by June 2021. The company was founded in Singapore but moved its headquarters to Boston this year after its Series B fundraise. In Singapore, Biofourmis has about 50 employees. The startup also has offices in India and Zurich.
Today, heart failure is the top global cause of hospitalisations for patients older than 65, where about 85 per cent of hospitalised patients suffer from an acute heart failure event at least once, and 43 per cent of patients are admitted at least four times.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: The Straits Times - 🏆 8. / 63 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: YahooSG - 🏆 3. / 71 Read more »
Source: The Straits Times - 🏆 8. / 63 Read more »
Source: BusinessTimes - 🏆 15. / 51 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »